# A Long Term Safety Study of BCX7353 in Hereditary Angioedema

> **NCT03472040** · PHASE2,PHASE3 · COMPLETED · sponsor: **BioCryst Pharmaceuticals** · enrollment: 387 (actual)

## Conditions studied

- Hereditary Angioedema
- HAE
- Prophylaxis

## Interventions

- **DRUG:** BCX7353

## Key facts

- **NCT ID:** NCT03472040
- **Lead sponsor:** BioCryst Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-16
- **Primary completion:** 2022-04-27
- **Final completion:** 2022-04-27
- **Target enrollment:** 387 (ACTUAL)
- **Last updated:** 2023-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03472040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03472040, "A Long Term Safety Study of BCX7353 in Hereditary Angioedema". Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/clinical/NCT03472040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*